14th Dec 2021 20:17
Diaceutics PLC - testing laboratories company - Wins a five year subscription contract with an unnamed global life sciences company to deliver customised data insights via its DXRX platform. The total contract value is in excess of USD1 million spread across five years and subject to milestones in year one and year three.
Chief Executive Officer Peter Keeling says: "This multi-year deal demonstrates the confidence which one of the acknowledged global leaders in diagnostics has in the quality of our Deductive Diagnostic Pathways, and the strength of the DXRX platform.
"This agreement represents another step towards our recurring, high margin and scalable multi-year subscription revenue targets and reinforces our belief in the opportunity for the DXRX platform, to serve multiple stakeholders across healthcare industry unlock the promise of Precision Medicine."
Current stock price: 100.50 pence
Year-to-date change: down 26%
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Diaceutics